Stocks / Stock overview

Perspective Therapeutics, Inc. (CATX)

$2.81+1.44%Aft $2.81 (-0.18%)Market cap $320.8M

NYSE American · Price as of · Nasdaq Real Time Price

Stock Scorer
Scoring…
Analyst consensus
Strong buy$12.29
  • Analysts14
  • Implied upside+337.2%
  • Target range$5.00 to $18.00
Analyst estimates are opinions, not forecasts of what the stock will do.
Source: Yahoo Finance consensus, retrieved
Next earnings
November 9, 2026date estimated
  • EPS expected-$0.25
  • A year ago-$0.35
  • Revenue expected$48,950 -77%
  • Estimate range-$0.31 to -$0.22
Consensus of 10 analysts for the quarter ending September 30, 2026. Beat the estimate in 2 of the last four quarters. Estimates are what Wall Street expects, not our forecast.
Source: Yahoo Finance earnings calendar

SEC filings

Source: SEC EDGARLatest filed

FormFiledDescription
8-KSeptember 8, 20268-K
4September 8, 2026STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
4September 4, 2026STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
4September 4, 2026STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
SCHEDULE 13D/ASeptember 4, 2026View on EDGAR
4September 3, 2026STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
4September 2, 2026STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
SCHEDULE 13G/AAugust 13, 2026View on EDGAR
All SEC filings

Articles that mention Perspective Therapeutics without it being the main subject.

What is a pod shop? Millennium didn't buy your stock. One of its 340 teams did.
Explainers

What is a pod shop? Millennium didn't buy your stock. One of its 340 teams did.

Citadel's last quarterly filing listed 15,589 positions. Millennium runs more than 340 separate investment teams and Point72 more than 200, which changes what a hedge fund stake in your stock actually means.

Jul 25, 2026

Frequently asked questions

When does CATX report earnings?

Perspective Therapeutics, Inc. (CATX) is scheduled to report quarterly results on November 9, 2026 (estimated). The 10-analyst consensus is -$0.25 per share on revenue of $48,950 for the quarter ending September 30, 2026, against -$0.35 and $209,000 a year earlier. It has beaten the consensus EPS estimate in 2 of the last four quarters. The date is an estimate from past reporting patterns and can move until the company confirms it.

What do analysts expect for CATX?

14 analysts cover Perspective Therapeutics, Inc. (CATX). The consensus rating is Strong buy. The average price target is $12.29, in a range of $5.00 to $18.00.

Are insiders buying or selling CATX?

We have no qualifying Form 4 insider purchases or sales on record for Perspective Therapeutics, Inc. (CATX). Sales are only tracked above a dollar threshold, so small routine trades may not appear.

Where can I see CATX SEC filings?

Recent filings are listed on this page, newest first. The latest is an 8-K filed September 8, 2026.

Data on this page comes from SEC EDGAR, public disclosure feeds and market data providers, and may be delayed or incomplete. Nothing here is investment advice.